SEARCH

SEARCH BY CITATION

References

  • 1
    Hirota S, Isozaki K, Moriyama Y, Kanakura Y, Nishida T, Ishigro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Shinomura Y, Kitamura Y. Gain-of-function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 57780.
  • 2
    Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 4: 1293301.
  • 3
    Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55: 196.
  • 4
    Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 3479.
  • 5
    Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrell L, Lu S-Z, Heitjan D, Ma Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 160914.
  • 6
    Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154: 16437.
  • 7
    Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 7267.
  • 8
    Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 2003; 94: 31520.
  • 9
    Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 47289.
  • 10
    Len Neckers. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S5561.
  • 11
    Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 2606.
  • 12
    Grenert JP, Sullivan WP, Fadden P, Haystead TAJ, Clark J, Mimnaugh E, Krutzsch H, Ochel H-J, Schulte TW, Sausville E, Neckers LM, Toft DO. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997; 272: 2384. 3–50.
  • 13
    Young JC, Hartl FU. Polypeptide release by HSP 90 involves ATP hydrolysis and is enhanced by the co-chaperon p23. EMBO J 2000; 19: 593040.
  • 14
    Schneider C, Sepp-Lorenzio L, Nimmesgern E, Ouerfelli O, Danisiieefsky S, Rosen N, Hartl FU. Pharmacological shifting of a balance between protein refolding and degradation mediated by HSP 90. Proc Natl Acad Sci USA 1996; 93: 1453641.
  • 15
    Loo MA, Jensen TJ, Cui L, Hou Y, Chang XB, Riordan JR. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by proteasome. EMBO J 1998; 17: 687987.
  • 16
    Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, Araki K, Akimaru K, Yuri K. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest 2002; 82: 6635.
  • 17
    Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U. Abberrant activation of c-KIT protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 2001; 61: 2006.
  • 18
    Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ, Pievotti MA. RET activation germline MEN2A MEN2B mutations. Oncogene 1995; 11: 241927.
  • 19
    Virginia C, Broudy NL, Lin W, Conrad L, Seth JC, O'Laughlin B, Mou S, Linnekin D. Signaling via src family kinases is required for normal internalization of the receptor c-KIT. Blood 1999; 94: 197986.